Somatization in major depression - clinical features and genetic associations

Acta Psychiatrica Scandinavica

Volumn 124, Issue 4, 2011, Pages 317-328

  Klengel, T ^a,b   Heck, A ^a   Pfister, H ^a   Bruckl T ^a   Hennings, J M ^a   Menke, A ^a   Czamara, D ^a   Muller Myhsok B ^a   Ising, M ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Candidate gene association study; Depressive disorder; Hydroxytryptamine receptor 2A; Major; Single nucleotide polymorphisms; Somatization disorder

Indexed keywords

CATECHOL METHYLTRANSFERASE; SERINE PROTEINASE OMI; SEROTONIN TRANSPORTER;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; DRD4 GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NOCICEPTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SLC6A2 GENE; SOMATIZATION; TPH1 GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CATECHOL O-METHYLTRANSFERASE; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PAIN PERCEPTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D4; SOMATOFORM DISORDERS; TREATMENT OUTCOME; TRYPTOPHAN HYDROXYLASE; YOUNG ADULT;

EID: 80052803442     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2011.01743.x     Document Type: Article

References (69)

1. Hiller W, Rief W, Brahler E. Somatization in the population: from mild bodily misperceptions to disabling symptoms. Soc Psychiatry Psychiatr Epidemiol 2006;41:704-712.
2. Mayou R, Kirmayer LJ, Simon G, Kroenke K, Sharpe M. Somatoform disorders: time for a new approach in DSM-V. Am J Psychiatry 2005;162:847-855.
3. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med 2003;65:528-533.
4. De Gucht V, Fischler B. Somatization: a critical review of conceptual and methodological issues. Psychosomatics 2002;43:1-9.
5. Vaccarino AL, Sills TL, Evans KR, Kalali AH. Prevalence and association of somatic symptoms in patients with Major Depressive Disorder. J Affect Disord 2008;110:270-276.
6. Denninger JW, Papakostas GI, Mahal Y et al. Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine. Psychosomatics 2006;47:348-352.
7. De Gucht V, Fischler B. Somatization: a critical review of conceptual and methodological issues. Psychosomatics 2002;43:1-9.
8. Simon GE, Vonkorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999;341:1329-1335.
9. Kirmayer LJ, Robbins JM, Dworkind M, Yaffe MJ. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993;150:734-741.
10. Garcia-Cebrian A, Gandhi P, Demyttenaere K, Peveler R. The association of depression and painful physical symptoms--a review of the European literature. Eur Psychiatry 2006;21:379-388.
11. Vaccarino AL, Sills TL, Evans KR, Kalali AH. Prevalence and association of somatic symptoms in patients with Major Depressive Disorder. J Affect Disord 2008;110:270-276.
12. Simon GE, Vonkorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999;341:1329-1335.
13. Gameroff MJ, Olfson M. Major depressive disorder, somatic pain, and health care costs in an urban primary care practice. J Clin Psychiatry 2006;67:1232-1239.
14. Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch Gen Psychiatry 2005;62:903-910.
15. Simon GE, Vonkorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999;341:1329-1335.
16. Kirmayer LJ, Robbins JM, Dworkind M, Yaffe MJ. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993;150:734-741.
17. Drayer RA, Mulsant BH, Lenze EJ et al. Somatic symptoms of depression in elderly patients with medical comorbidities. Int J Geriatr Psychiatry 2005;20:973-982.
18. Sayuk GS, Elwing JE, Lustman PJ, Clouse RE. High somatic symptom burdens and functional gastrointestinal disorders. Clin Gastroenterol Hepatol 2007;5:556-562.
19. Papakostas GI, Petersen T, Denninger J et al. Somatic symptoms in treatment-resistant depression. Psychiatry Res 2003;118:39-45.
20. Agosti V, Quitkin FM, Stewart JW, Mcgrath PJ. Somatization as a predictor of medication discontinuation due to adverse events. Int Clin Psychopharmacol 2002;17:311-314.
21. Terre L, Poston WS, Foreyt J, St JS. Do somatic complaints predict subsequent symptoms of depression? Psychother Psychosom 2003;72:261-267.
22. Nakao M, Yano E. Somatic symptoms for predicting depression: one-year follow-up study in annual health examinations. Psychiatry Clin Neurosci 2006;60:219-225.
23. Kinnunen P, Laukkanen E, Kylma J. Associations between psychosomatic symptoms in adolescence and mental health symptoms in early adulthood. Int J Nurs Pract 2010;16:43-50.
24. Ising M, Lauer CJ, Holsboer F, Modell S. The Munich vulnerability study on affective disorders: premorbid psychometric profile of affected individuals. Acta Psychiatr Scand 2004;109:332-338.
25. Kendler KS, Walters EE, Truett KR et al. A twin-family study of self-report symptoms of panic-phobia and somatization. Behav Genet 1995;25:499-515.
26. Hennings A, Zill P, Rief W. Serotonin transporter gene promoter polymorphism and somatoform symptoms. J Clin Psychiatry 2009;70:1536-1539.
27. Gonda X, Fountoulakis KN, Juhasz G et al. Association of the s allele of the 5-HTTLPR with neuroticism-related traits and temperaments in a psychiatrically healthy population. Eur Arch Psychiatry Clin Neurosci 2009;259:106-113.
28. Serretti A, Mandelli L, Lorenzi C et al. Serotonin transporter gene influences the time course of improvement of "core" depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders. Psychiatry Res 2007;149:185-193.
29. Rief W, Pilger F, Ihle D, Verkerk R, Scharpe S, Maes M. Psychobiological aspects of somatoform disorders: contributions of monoaminergic transmitter systems. Neuropsychobiology 2004;49:24-29.
30. Yu W, Gwinn M, Clyne M, Yesupriya A, Khoury MJ. A navigator for human genome epidemiology. Nat Genet 2008;40:124-125.
31. Hennings JM, Owashi T, Binder EB et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009;43:215-229.
32. Ising M, Lucae S, Binder EB et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 2009;66:966-975.
33. Binder EB, Salyakina D, Lichtner P et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004;36:1319-1325.
34. AMERICAN PSYCHIATRIC ASSOCIATION. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders. Washington (DC): American Psychiatric Association, 1994.
35. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
36. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296.
37. Rhoades HM, Overall JE. The Hamilton Depression Scale - Factor Scoring and Profile Classification. Psychopharmacol Bull 1983;19:91-96.
38. Franke GH. Symptom-Checkliste von L.R. Derogatis - Deutsche Version (SCL-90-R). 2., vollständig überarbeitete und neu normierte Auflage. Göttingen: Beltz Test, 2002.
39. Derogatis LR. SCL-90-R, Administration, Scoring & Procedures Manual-I for R(evides) Version. Baltimore: John Hopkins University School of Medicine, 1977.
40. Kendler KS, Walters EE, Truett KR et al. A twin-family study of self-report symptoms of panic-phobia and somatization. Behav Genet 1995;25:499-515.
41. CIPS. Internationale Skalen für Psychiatrie (4., überarbeitete und erweiterte Auflage). Göttingen: Beltz Test GmbH, 1998.
42. Hamilton M. Hamilton Anxiety Scale. In: Guy W, ed. ECDEU Assessment manual for psychopharmacology. Rev. Ed. NIMH: Rockville, Maryland, 1976:193-198.
43. Laux L, Glanzmann P, Schaffner P, Spielberger CD. Das State-Trait-Angstinventar. Theoretische Grundlagen und Handanweisung. Weinheim: Beltz Test GmbH, 1981.
44. Spielberger CD, Gorsuch RL, Lushene RE. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press, 1970.
45. Yu W, Gwinn M, Clyne M, Yesupriya A, Khoury MJ. A navigator for human genome epidemiology. Nat Genet 2008;40:124-125.
46. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 2005;76:887-893.
47. Westfall PH, Young SS. Resampling-Based Multiple Testing: Examples and Methods for p-value Adjustment. New York: Wiley, 1993.
48. Zaykin DV, Zhivotovsky LA, Westfall PH, Weir BS. Truncated product method for combining P-values. Genet Epidemiol 2002;22:170-185.
49. Hennings JM, Owashi T, Binder EB et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009;43:215-229.
50. Kohli M, Salyakina D, Pfennig A et al. Association of genetic variants in the neurotrophic receptor-encoding gene NTRK2 and a lifetime history of suicide attempts in depressed patients. Arch Gen Psychiatry 2010;67:348-359.
51. Agosti V, Quitkin FM, Stewart JW, Mcgrath PJ. Somatization as a predictor of medication discontinuation due to adverse events. Int Clin Psychopharmacol 2002;17:311-314.
52. Sayuk GS, Elwing JE, Lustman PJ, Clouse RE. High somatic symptom burdens and functional gastrointestinal disorders. Clin Gastroenterol Hepatol 2007;5:556-562.
53. Papakostas GI, Petersen T, Denninger J et al. Somatic symptoms in treatment-resistant depression. Psychiatry Res 2003;118:39-45.
54. Hiller W, Rief W, Brahler E. Somatization in the population: from mild bodily misperceptions to disabling symptoms. Soc Psychiatry Psychiatr Epidemiol 2006;41:704-712.
55. Gureje O, Simon GE, Ustun TB, Goldberg DP. Somatization in cross-cultural perspective: a World Health Organization study in primary care. Am J Psychiatry 1997;154:989-995.
56. Lieb R, Meinlschmidt G, Araya R. Epidemiology of the association between somatoform disorders and anxiety and depressive disorders: an update. Psychosom Med 2007;69:860-863.
57. Lipsanen T, Saarijarvi S, Lauerma H. Exploring the relations between depression, somatization, dissociation and alexithymia--overlapping or independent constructs? Psychopathology 2004;37:200-206.
58. Holliday KL, Macfarlane GJ, Nicholl BI, Creed F, Thomson W, Mcbeth J. Genetic variation in neuroendocrine genes associates with somatic symptoms in the general population: results from the EPIFUND study. J Psychosom Res 2010;68:469-474.
59. Hennings A, Zill P, Rief W. Serotonin transporter gene promoter polymorphism and somatoform symptoms. J Clin Psychiatry 2009;70:1536-1539.
60. Lazary J, Lazary A, Gonda X et al. New evidence for the association of the serotonin transporter gene (SLC6A4) haplotypes, threatening life events, and depressive phenotype. Biol Psychiatry 2008;64:498-504.
61. Brezo J, Bureau A, Merette C et al. Differences and similarities in the serotonergic diathesis for suicide attempts and mood disorders: a 22-year longitudinal gene-environment study. Mol Psychiatry 2010;15:831-843.
62. Heck A, Lieb R, Ellgas A et al. Investigation of 17 candidate genes for personality traits confirms effects of the HTR2A gene on novelty seeking. Genes Brain Behav 2009;8:464-472.
63. Horstmann S, Binder EB. Pharmacogenomics of antidepressant drugs. Pharmacol Ther 2009;124:57-73.
64. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010;15:473-500.
65. Rief W, Hennings A, Riemer S, Euteneuer F. Psychobiological differences between depression and somatization. J Psychosom Res 2010;68:495-502.
66. Papakostas GI, Petersen TJ, Iosifescu DV et al. Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. J Clin Psychiatry 2004;65:543-546.
67. Papakostas GI, Petersen T, Denninger J et al. Somatic symptoms in treatment-resistant depression. Psychiatry Res 2003;118:39-45.
68. Agosti V, Quitkin FM, Stewart JW, Mcgrath PJ. Somatization as a predictor of medication discontinuation due to adverse events. Int Clin Psychopharmacol 2002;17:311-314.
69. Ozturk E, Sar V. Somatization as a predictor of suicidal ideation in dissociative disorders. Psychiatry Clin Neurosci 2008;62:662-668.